GefitinibAcquired drug resistance in EGFR-mutated bone metastasised lung adenocarcinoma: case report

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2019年 / 1778卷 / 1期
关键词：
D O I：
10.1007/s40278-019-71017-8
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：214 / 214
相关论文
共 50 条
  • [31] Overcoming EGFR-TKI resistance in EGFR-mutated lung cancer
    Gardizi, M.
    Scheffler, M.
    Bos, M.
    Geist, T.
    Heukamp, L.
    Nogova, L.
    Toepelt, K.
    Fernandez-Cuesta, L.
    Culmann, H.
    Kaminsky, B.
    Panse, J.
    Becker, C.
    Mattonet, C.
    Serke, M.
    Schmitz, S.
    Schnell, R.
    Galetke, W.
    Hekmat, K.
    Buettner, R.
    Wolf, J.
    ONKOLOGIE, 2013, 36 : 30 - 30
  • [32] GefitinibAcquired resistance and adenocarcinoma transformation to small cell lung cancer: case report
    Reactions Weekly, 2017, 1678 (1) : 91 - 91
  • [33] GefitinibAcquired resistance and adenocarcinoma transformation to small cell lung cancer: case report
    Reactions Weekly, 2017, 1659 (1) : 134 - 134
  • [34] Bone metastasis reduces responsiveness to EGFR-TKIs in patients with EGFR-mutated advanced lung adenocarcinoma.
    Jiang, Kan
    Lin, Gen
    Zheng, Xinlong
    Long, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report
    Aubanel, Marjorie
    Swalduz, Aurelie
    Avrillon, Virginie
    Doublet, Louis
    Mastroianni, Benedicte
    Neidhardt-Berard, Eve-Marie
    Perol, Maurice
    CLINICAL LUNG CANCER, 2020, 21 (06) : E601 - E606
  • [36] Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma
    Aredo, J.
    Wakelee, H. A.
    Neal, J.
    Padda, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S619 - S619
  • [37] Achievement of pathological complete response with osimertinib for EGFR-mutated lung adenocarcinoma
    Fujita, Yasuhiro
    Take, Nobuyuki
    Shinohara, Shinji
    Mori, Masataka
    Kanayama, Masatoshi
    Takenaka, Masaru
    Kuroda, Koji
    Shimajiri, Shohei
    Tanaka, Fumihiro
    GENERAL THORACIC AND CARDIOVASCULAR SURGERY CASES, 2023, 2 (01):
  • [38] Severe cardiotoxicity induced by osimertinib in a patient with EGFR-mutated adenocarcinoma of the lung
    Tanaka, Takaaki
    Nii, Soma
    Yamaoka, Hidenaru
    Fujimoto, Nobukazu
    BMJ CASE REPORTS, 2023, 16 (07)
  • [39] Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFR-mutated lung adenocarcinoma: a report of two cases
    Uruga, Hironori
    Fujii, Takeshi
    Nakamura, Nobuyuki
    Moriguchi, Shuhei
    Kishi, Kazuma
    Takaya, Hisashi
    RESPIROLOGY CASE REPORTS, 2020, 8 (02):
  • [40] EGFR-Mutated Pulmonary Choriocarcinoma Combined With Adenocarcinoma
    Shigematsu, Yasuyuki
    Nakano, Kaoru
    Uchibori, Ken
    Inamura, Kentaro
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (11) : 1318 - 1322
12345